JP2013126979A - 癌の処置のためのイノツズマブオゾガマイシンおよびトーリセルの組合わせ - Google Patents

癌の処置のためのイノツズマブオゾガマイシンおよびトーリセルの組合わせ Download PDF

Info

Publication number
JP2013126979A
JP2013126979A JP2012273427A JP2012273427A JP2013126979A JP 2013126979 A JP2013126979 A JP 2013126979A JP 2012273427 A JP2012273427 A JP 2012273427A JP 2012273427 A JP2012273427 A JP 2012273427A JP 2013126979 A JP2013126979 A JP 2013126979A
Authority
JP
Japan
Prior art keywords
cancer
temsirolimus
pharmaceutically acceptable
inotuzumab ozogamicin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012273427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013126979A5 (enExample
Inventor
Andreas Bruederle
アンドレアス・ブリューデルレ
Padraig Moran
パドレイグ・モラン
Anastasios Stathis
アナスタシオス・スタシス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONCOLOGY INST OF SOUTHERN SWITZERLAND
Pfizer Inc
Original Assignee
ONCOLOGY INST OF SOUTHERN SWITZERLAND
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONCOLOGY INST OF SOUTHERN SWITZERLAND, Pfizer Inc filed Critical ONCOLOGY INST OF SOUTHERN SWITZERLAND
Publication of JP2013126979A publication Critical patent/JP2013126979A/ja
Publication of JP2013126979A5 publication Critical patent/JP2013126979A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012273427A 2011-12-16 2012-12-14 癌の処置のためのイノツズマブオゾガマイシンおよびトーリセルの組合わせ Pending JP2013126979A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576831P 2011-12-16 2011-12-16
US61/576,831 2011-12-16

Publications (2)

Publication Number Publication Date
JP2013126979A true JP2013126979A (ja) 2013-06-27
JP2013126979A5 JP2013126979A5 (enExample) 2016-02-04

Family

ID=47557418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012273427A Pending JP2013126979A (ja) 2011-12-16 2012-12-14 癌の処置のためのイノツズマブオゾガマイシンおよびトーリセルの組合わせ

Country Status (13)

Country Link
US (1) US9642918B2 (enExample)
EP (1) EP2790723A1 (enExample)
JP (1) JP2013126979A (enExample)
KR (2) KR20140107413A (enExample)
CN (1) CN104023747A (enExample)
AU (2) AU2012351728A1 (enExample)
BR (1) BR112014014181A2 (enExample)
CA (1) CA2859089A1 (enExample)
HK (1) HK1201191A1 (enExample)
IL (1) IL233165A0 (enExample)
MX (1) MX2014007077A (enExample)
RU (1) RU2607594C2 (enExample)
WO (1) WO2013088304A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517744A (ja) * 2015-06-15 2018-07-05 ニューサウス イノベーションズ プロプライアタリー リミティド 有機アルセノキシド化合物とｍＴＯＲ阻害剤の組合せ医薬
JP2022523763A (ja) * 2019-02-13 2022-04-26 コイミューン インコーポレイテッド キメラ抗原受容体を発現する細胞とモノクローナル抗体との組み合わせを用いたがん免疫療法
JP2022551909A (ja) * 2019-10-10 2022-12-14 ブライオロジクス インコーポレイテッド ブリオスタチンによる腫瘍関連抗原の誘導方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CA3066350A1 (en) * 2017-06-06 2018-12-13 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2009536632A (ja) * 2006-05-11 2009-10-15 ノバルティス アクチエンゲゼルシャフト 医薬組合せ剤
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
US20110118297A1 (en) * 2009-11-13 2011-05-19 Pankaj Bhargava Tivozanib and Temsirolimus in Combination
WO2011134899A1 (en) * 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4667637A (en) 1986-01-08 1987-05-26 Brunswick Corporation Gated knock detector for internal-combustion engines
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
WO2007125252A1 (fr) 2006-04-26 2007-11-08 France Telecom Procede et systeme de gestion d'un paiement electronique
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2009536632A (ja) * 2006-05-11 2009-10-15 ノバルティス アクチエンゲゼルシャフト 医薬組合せ剤
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
US20110118297A1 (en) * 2009-11-13 2011-05-19 Pankaj Bhargava Tivozanib and Temsirolimus in Combination
WO2011134899A1 (en) * 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD REVIEWS, vol. 24, no. 2, JPN6016036542, 2010, pages 69 - 82, ISSN: 0003403202 *
DRUGS, vol. 71, no. 4, JPN6016036543, March 2011 (2011-03-01), pages 415 - 442, ISSN: 0003403203 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 12, JPN6016036544, 2010, pages 2085 - 2093, ISSN: 0003403204 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517744A (ja) * 2015-06-15 2018-07-05 ニューサウス イノベーションズ プロプライアタリー リミティド 有機アルセノキシド化合物とｍＴＯＲ阻害剤の組合せ医薬
JP2022523763A (ja) * 2019-02-13 2022-04-26 コイミューン インコーポレイテッド キメラ抗原受容体を発現する細胞とモノクローナル抗体との組み合わせを用いたがん免疫療法
JP2022551909A (ja) * 2019-10-10 2022-12-14 ブライオロジクス インコーポレイテッド ブリオスタチンによる腫瘍関連抗原の誘導方法

Also Published As

Publication number Publication date
KR20170049617A (ko) 2017-05-10
CN104023747A (zh) 2014-09-03
BR112014014181A2 (pt) 2017-06-13
CA2859089A1 (en) 2013-06-20
AU2012351728A1 (en) 2014-06-19
AU2016202621B2 (en) 2017-11-02
MX2014007077A (es) 2015-03-06
RU2014124005A (ru) 2016-02-10
KR20140107413A (ko) 2014-09-04
US20140335109A1 (en) 2014-11-13
IL233165A0 (en) 2014-07-31
WO2013088304A1 (en) 2013-06-20
AU2016202621A1 (en) 2016-05-26
EP2790723A1 (en) 2014-10-22
US9642918B2 (en) 2017-05-09
HK1201191A1 (en) 2015-08-28
RU2607594C2 (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
AU2016202621B2 (en) Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
KR102662228B1 (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20200069694A1 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
JP2020172487A (ja) トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
RS58944B1 (sr) Pertuzumab, trastuzumab, docetaksel i karboplatin za lečenje raka dojke u ranoj fazi
US11325980B2 (en) Combination therapy using a LIV1-ADC and a chemotherapeutic
CN105451770A (zh) 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
JP2017530983A (ja) 相乗的オーリスタチン組合せ
JP7145891B2 (ja) 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
JP2018516968A (ja) 医薬組み合わせおよびその使用
CN105899237A (zh) 用于治疗子宫内膜癌的倍癌霉素adc
WO2013023043A2 (en) Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
CN114302746A (zh) 包含抗cd25抗体药物缀合物和另一剂的组合疗法
JP2021073203A (ja) Ｈｅｒ２陽性転移性乳癌の治療方法
WO2012177440A1 (en) Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
TW202233206A (zh) Ｓｔｉｎｇ促效劑、檢查點抑制劑及輻射之投與
WO2025186213A1 (en) Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
WO2026082894A1 (en) Ceacam5 antibody-drug conjugate for use in cancer therapy
HK1189490A (en) Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
HK1226957A1 (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171031